The FDA approved a prescription tongue muscle stimulation device that claims to reduce mild sleep apnea and snoring in patients with obstructive sleep apnea.
The FDA recently announced the approval of a prescription tongue muscle stimulation device that claims to reduce mild obstructive sleep apnea (OSA) and snoring. The device, called eXciteOSA, is approved through the de novo regulatory pathway for people 18 years and older.
Compared with prior devices used at nighttime for the treatment of OSA, such as continuous positive airway pressure therapy, eXciteOSA would be the first device to improve tongue muscle function while awake, which over time can prevent the tongue from collapsing backward and obstructing the airway during sleep.
The approval comes after the FDA assessed the safety and effectiveness of the device in 115 patients with snoring, including 48 patients with comorbid snoring and mild sleep apnea. Each participant underwent eXciteOSA therapy for 20 minutes once a day for 6 weeks.
After being reassessed 2 weeks following therapy discontinuation, the percent of time spent snoring at levels louder than 40dB, the noise level at which snoring begins to impact sleep, was found to be reduced by more than 20% in three-fourths of the patient cohort (n = 87). Moreover, among patients with comorbid snoring and mild sleep apnea, average levels of the Apnea Hypopnea Index (AHI) fell by 48%, from 10.21 to 5.27, in 41 of the 48 patients.
“Obstructive sleep apnea not only impacts sleep quality, but can have other serious health impacts if untreated. Today’s authorization offers a new option for the thousands of individuals who experience snoring or mild sleep apnea,” said Malvina Eydelman, MD, director of the Office of Ophthalmic, Anesthesia, Respiratory, ENT and Dental Devices in the FDA’s Center for Devices and Radiological Health, in a statement.
Through a silicone mouthpiece with 4 electrodes distributed above and below the tongue, the device delivers electrical muscle stimulation in sessions that consist of a series of electrical pulses, with rest periods in between. Similar to the study, its recommended use is for 20 minutes once a day during a wakeful state for 6 weeks and once a week after initial therapy.
Notably, eXciteOSA is not intended for patients with diagnosed severe OSA, represented by AHI levels of 15 and higher. The device is also contraindicated for patients with pacemakers or implanted pacing leads, who are pregnant, who have ulcerations in or around the mouth, and who have various dental and orthodontic hardware, such as dental braces.
A comprehensive dental examination was additionally recommended prior to use of the device, with the most common adverse events including excessive salivation, tongue or tooth discomfort, tongue tingling, dental filling sensitivity, metallic taste, gagging, and tight jaw.
The FDA’s marketing authorization was granted to Signifier Medical Technologies, LLC, who manufactures eXciteOSA.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More